MX2019014330A - Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. - Google Patents
Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax.Info
- Publication number
- MX2019014330A MX2019014330A MX2019014330A MX2019014330A MX2019014330A MX 2019014330 A MX2019014330 A MX 2019014330A MX 2019014330 A MX2019014330 A MX 2019014330A MX 2019014330 A MX2019014330 A MX 2019014330A MX 2019014330 A MX2019014330 A MX 2019014330A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- lymphoma
- venetoclax
- antibody
- paradigm
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001183 venetoclax Drugs 0.000 title abstract 3
- 238000011284 combination treatment Methods 0.000 title 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 3
- 206010045170 Tumour lysis syndrome Diseases 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000010380 tumor lysis syndrome Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación proporciona anticuerpos anti-CD19 y venetoclax para su uso en el tratamiento del linfoma no Hodgkin, la leucemia linfocítica crónica y/o el linfoma linfocítico de células pequeñas. Los anticuerpos anti-CD19, en particular, MOR00208 y venetoclax se administran a pacientes que padecen linfoma no Hodgkin (NHL), leucemia linfocítica crónica (CLL) y/o linfoma linfocítico de células pequeñas (SLL) de acuerdo con un paradigma de tratamiento específico para mitigar el síndrome de lisis tumoral asociado con la terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173712 | 2017-05-31 | ||
| PCT/EP2018/064229 WO2018220040A1 (en) | 2017-05-31 | 2018-05-30 | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014330A true MX2019014330A (es) | 2020-02-05 |
Family
ID=59070416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014330A MX2019014330A (es) | 2017-05-31 | 2018-05-30 | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. |
| MX2023013228A MX2023013228A (es) | 2017-05-31 | 2019-11-28 | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013228A MX2023013228A (es) | 2017-05-31 | 2019-11-28 | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP3630177B1 (es) |
| JP (2) | JP7399713B2 (es) |
| KR (2) | KR20240117655A (es) |
| CN (1) | CN110678201A (es) |
| AU (1) | AU2018276384B2 (es) |
| BR (1) | BR112019025034A2 (es) |
| CA (1) | CA3062400A1 (es) |
| DK (1) | DK3630177T5 (es) |
| ES (1) | ES2961940T3 (es) |
| FI (1) | FI3630177T3 (es) |
| HR (1) | HRP20231229T1 (es) |
| HU (1) | HUE063119T2 (es) |
| IL (2) | IL270855B2 (es) |
| LT (1) | LT3630177T (es) |
| MA (1) | MA48751B1 (es) |
| MD (1) | MD3630177T2 (es) |
| MX (2) | MX2019014330A (es) |
| PL (1) | PL3630177T3 (es) |
| PT (1) | PT3630177T (es) |
| RS (1) | RS64746B1 (es) |
| SG (1) | SG11201909715VA (es) |
| SI (1) | SI3630177T1 (es) |
| SM (1) | SMT202300338T1 (es) |
| WO (1) | WO2018220040A1 (es) |
| ZA (1) | ZA201907369B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056408T2 (hu) | 2015-08-21 | 2022-02-28 | Morphosys Ag | Kombinációk és alkalmazásaik |
| AU2017348624B2 (en) * | 2016-10-28 | 2024-09-26 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| EP4251138A1 (en) * | 2020-11-30 | 2023-10-04 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| WO2022115120A1 (en) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8097703B2 (en) | 2005-06-20 | 2012-01-17 | Medarex, Inc. | CD19 antibodies and their uses |
| PT2270050E (pt) | 2005-12-30 | 2013-09-12 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| PL2059536T3 (pl) | 2006-08-14 | 2014-07-31 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| ES2383710T3 (es) | 2006-09-08 | 2012-06-25 | Medimmune, Llc | Anticuerpos anti-CD19 humanizados y su uso en el tratamiento de tumores, trasplantes y enfermedades autoinmunes |
| EP2211904B1 (en) | 2007-10-19 | 2016-08-17 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| DK2744515T3 (da) | 2011-08-16 | 2022-03-28 | Morphosys Ag | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep |
| EP2744826B1 (en) | 2011-08-16 | 2022-02-09 | MorphoSys AG | Combination therapy with an anti-cd19 antibody and a purine analog |
| HUE056408T2 (hu) | 2015-08-21 | 2022-02-28 | Morphosys Ag | Kombinációk és alkalmazásaik |
| AU2017348624B2 (en) | 2016-10-28 | 2024-09-26 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
-
2018
- 2018-05-30 CN CN201880035726.5A patent/CN110678201A/zh active Pending
- 2018-05-30 LT LTEPPCT/EP2018/064229T patent/LT3630177T/lt unknown
- 2018-05-30 WO PCT/EP2018/064229 patent/WO2018220040A1/en active Application Filing
- 2018-05-30 FI FIEP18728153.0T patent/FI3630177T3/fi active
- 2018-05-30 PL PL18728153.0T patent/PL3630177T3/pl unknown
- 2018-05-30 SG SG11201909715V patent/SG11201909715VA/en unknown
- 2018-05-30 DK DK18728153.0T patent/DK3630177T5/da active
- 2018-05-30 MD MDE20200316T patent/MD3630177T2/ro unknown
- 2018-05-30 CA CA3062400A patent/CA3062400A1/en active Pending
- 2018-05-30 KR KR1020247024908A patent/KR20240117655A/ko not_active Application Discontinuation
- 2018-05-30 SI SI201831004T patent/SI3630177T1/sl unknown
- 2018-05-30 IL IL270855A patent/IL270855B2/en unknown
- 2018-05-30 AU AU2018276384A patent/AU2018276384B2/en active Active
- 2018-05-30 ES ES18728153T patent/ES2961940T3/es active Active
- 2018-05-30 BR BR112019025034-4A patent/BR112019025034A2/pt unknown
- 2018-05-30 KR KR1020197037961A patent/KR20200010472A/ko active Application Filing
- 2018-05-30 HU HUE18728153A patent/HUE063119T2/hu unknown
- 2018-05-30 EP EP18728153.0A patent/EP3630177B1/en active Active
- 2018-05-30 JP JP2019565795A patent/JP7399713B2/ja active Active
- 2018-05-30 MA MA48751A patent/MA48751B1/fr unknown
- 2018-05-30 HR HRP20231229TT patent/HRP20231229T1/hr unknown
- 2018-05-30 RS RS20230937A patent/RS64746B1/sr unknown
- 2018-05-30 IL IL297461A patent/IL297461B2/en unknown
- 2018-05-30 MX MX2019014330A patent/MX2019014330A/es unknown
- 2018-05-30 PT PT187281530T patent/PT3630177T/pt unknown
- 2018-05-30 SM SM20230338T patent/SMT202300338T1/it unknown
- 2018-05-30 EP EP23190328.7A patent/EP4268900A3/en active Pending
-
2019
- 2019-11-06 ZA ZA2019/07369A patent/ZA201907369B/en unknown
- 2019-11-28 MX MX2023013228A patent/MX2023013228A/es unknown
-
2023
- 2023-12-06 JP JP2023205931A patent/JP2024028865A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013228A (es) | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. | |
| PH12019502661A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
| MX2019011858A (es) | Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos. | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| BR112016025437A2 (pt) | combinação de lenalidomida e construto de polipeptídeo, e usos destes | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| PH12021550553A1 (en) | Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell | |
| AU2017228470A8 (en) | Combination therapy with anti-CD73 antibodies | |
| MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2021005761A (es) | Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados. | |
| MX2018010672A (es) | Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada. | |
| SA523440623B1 (ar) | أجسام مضادة | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MX353589B (es) | Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina. | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| EA201792058A1 (ru) | Виротерапия комбинацией антител | |
| MX354479B (es) | Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno. | |
| MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
| MX2020013103A (es) | Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. | |
| WO2019070161A3 (en) | Articles and methods directed to personalized therapy of cancer | |
| PH12021551138A1 (en) | Application of chidamide in combination with r-chop, and drug combination | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| PH12022551008A1 (en) | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| CR20220149A (es) | Dosis para anticuerpos anti-triptasa |